Printer Friendly
The Free Library
4,489,051 articles and books
Member login
User name  
Password 
 
Join us Forgot password?

Browse Antineoplastic agents topic

Subtopics (48)

 

Articles

1-100 out of 100 article(s)
Title Author Type Date Words
HANA BIOSCIENCES GETS U.S.ORPHAN DRUG DESIGNATION FOR MARQIBO. Aug 1, 2008 664
ZIOPHARM Presents Safety and Preliminary Efficacy Data from Two Phase I Studies of Indibulin at AACR Centennial Conference. Conference news Jul 23, 2008 661
OncoVista Innovative Therapies to Begin Enrolling Patients in a Phase I/II Study of Cordycepin in Patients with Refractory TdT-Positive Leukemia. Jul 22, 2008 437
Curis Selects Hsp90 Inhibitor CUDC-305 as Development Candidate from Targeted Cancer Drug Development Platform. Jul 21, 2008 1275
The Multiple Myeloma Research Consortium (MMRC) Announces the Initiation of Phase I/II Study of Elotuzumab (Huluc63) Monoclonal Antibody in Combination with Velcade. Report Jul 18, 2008 677
GPC Biotech To Re-Schedule Annual Shareholders' Meeting. Jul 17, 2008 318
ERBITUX(R) (Cetuximab) Receives Approval in Japan for Use in Advanced Colorectal Cancer. Jul 16, 2008 2133
Oncolin Therapeutics Announces Appointment of Chair of Scientific Advisory Committee. Jul 16, 2008 373
The DNA Repair Company Licenses Test Predictive of Poor Outcomes to Breast Cancer Therapy. Jul 15, 2008 602
Cyclacel Publishes Study of Seliciclib Synergy with Tarceva and Herceptin in Journal Clinical Cancer Research. Jul 14, 2008 1284
Introgen to Host Conference Call with Clinical Investigators to Discuss Phase III Data and ADVEXIN Registration Activities. Jul 8, 2008 589
Fluxion Biosciences Wins R&D 100 Award. Jul 3, 2008 430
The Principal Financial Group Takes Some of the Bite Out of Cancer Treatments. Jul 2, 2008 540
Implications Of The Emerging Patent Litigation In India. Jul 1, 2008 1433
SATRAPLATIN SPARC PHASE3 PROSTATE CANCER DATA REPORTED. Jul 1, 2008 1034
Cancer Cells Revert to Normal at Specific Signal Threshold, Stanford Researchers Find. Jul 1, 2008 873
A Report by Leading Clinical Researchers on the Current Quantitative Imaging Tools for Lung Cancer Drug Assessment. Jun 30, 2008 348
Gemin X Pharmaceuticals, Inc. Closes $38 Million Series C Financing to Advance Lead Cancer Drug, Obatoclax, Into Registration Trials. Jun 30, 2008 474
Introgen Submits ADVEXIN(R) Regulatory Applications in the U.S. and Europe. Jun 30, 2008 1103
New Data Show Preemptive Treatment May Significantly Reduce Skin Toxicities in Patients Receiving Vectibix(R) (Panitumumab). Clinical report Jun 26, 2008 1970
IMC-A12 Plus Temsirolimus Clinical Trial for Advanced Cancer Opens for Patient Enrollment. Jun 25, 2008 1173
CB1400, Patented by Canopus BioPharma, Enters Phase II Clinical Trials for the Prevention of Mucositis in Patients with Cancer of the Head and Neck. Jun 23, 2008 391
The International Myeloma Foundation Says Previously Untreated Patients Could Benefit from FDA Approval of VELCADE(R) for 'Front-Line' Use. Jun 23, 2008 556
Dutton Associates Announces Investment Opinion: CEL-SCI Strong Speculative Buy Rating In Update Coverage By Dutton Associates. Jun 23, 2008 474
BioInvent and ThromboGenics Announce a Strategic Alliance with Roche for TB-403, A Novel Anti-Cancer Antibody. Jun 18, 2008 1395
SIR-Spheres(R) Microspheres Featured at the 2008 Society of Nuclear Medicine Annual Meeting. Jun 13, 2008 459
GPC Biotech Announces Granting of European Patent Related to Satraplatin for Treating Tumors Resistant or Refractory to Taxanes. Jun 12, 2008 838
OHSU Cancer Institute to Use Sequenom's MassARRAY Technology for Cancer Research. Jun 9, 2008 602
Novelix Pharmaceuticals, Inc. Relocates to La Jolla, Expands Team and Closes Series A-3 Preferred Stock Financing. Jun 5, 2008 299
Horse Power For Life Receives Grant to Increase Cancer Therapy Efforts. Jun 3, 2008 305
New Data from Several Satraplatin Clinical Trials in Solid Tumors Presented at 44th ASCO Annual Meeting. Jun 2, 2008 1659
Data from Satraplatin SPARC Phase 3 Trial in Patients with Hormone-Refractory Prostate Cancer Progressing after Initial Chemotherapy Presented at 44th ASCO Annual Meeting. Jun 2, 2008 1251
Geron Presentations at the ASCO 2008 Annual Meeting. Jun 2, 2008 705
Seattle Genetics Announces Initiation of SGN-40 Phase Ib Clinical Trial in Combination With Velcade for Multiple Myeloma. Jun 2, 2008 829
Oncologic and Triton BioSystems Merge to Form Aduro BioTech. Jun 2, 2008 567
ONCODESIGN Secures US $4.7 Million in Financing. Jun 2, 2008 473
Retired Football Player Elijah Alexander Attends International Cancer Conference to Encourage Young Patients. Jun 2, 2008 435
Updated Data from Ongoing Phase 3 Trials Support the Continued Study of Vectibix(R) (panitumumab) in Combination with Standard Chemotherapy. Jun 1, 2008 2206
New Analyses of Pivotal Phase 3 Study of ERBITUX(R) Demonstrate Enhanced Efficacy in First-Line Metastatic Colorectal Cancer Patients with Wild-Type K-Ras Biomarker. Jun 1, 2008 2178
Medicinal plants face extinction. Sherman, Lisa Jun 1, 2008 135
Amgen Presents New Data at ASCO on Four Investigational Molecules from Oncology Pipeline. May 31, 2008 2147
ERBITUX(R) (Cetuximab) Data Demonstrate Improved Overall Survival in First-Line Treatment of Advanced Non-Small Cell Lung Cancer. Clinical report May 31, 2008 2583
RTOG Study: Adding Cetuximab to Chemotherapy and Radiotherapy Leads to Improved Outcome for Lung Cancer Patients. Clinical report May 31, 2008 2392
Locus Pharmaceuticals Initiates Strategic Inflammatory Cancer Research Collaborations. May 30, 2008 1093
Vall d'Hebron University Hospital and Cyclacel to Initiate Phase 1 Combination Study of Seliciclib and Tarceva(R) in Advanced Cancers. May 29, 2008 1094
GPC Biotech Announces Data from Several Satraplatin Clinical Trials to be Presented at ASCO Annual Meeting. May 28, 2008 499
Odanacatib, Merck's Investigational Cathepsin K Inhibitor, Reduced Markers of Bone Turnover in Women with Breast Cancer and Bone Metastases. May 27, 2008 1062
Nanomedicine Company Nanobiotix Elects Former Sanofi-Aventis Oncology Researcher Elsa Borghi, MD, as its Medical Director. May 27, 2008 431
ImmunoGen, Inc. Announces Presentations at Upcoming 2008 American Society of Clinical Oncology Annual Meeting. May 23, 2008 407
AVEO Pharmaceuticals Granted Patent for Unique Genetic Screen to Identify Novel Cancer Drug Targets. May 22, 2008 667
Sirtex Launches Global Clinical Trial Comparing the Use of SIR-Spheres(R) Microspheres Plus Chemotherapy versus Chemotherapy Alone as First Line Treatment for Metastatic Colorectal Cancer. Clinical report May 21, 2008 600
Ore Pharmaceuticals CEO Charles Dimmler Presents Compound Status and Patent Development at Rodman & Renshaw 5th Annual Global Healthcare Conference. Conference news May 19, 2008 930
Array BioPharma and AstraZeneca Announce New Phase 2 Development Plans for the Investigational Anti-Cancer Drug AZD6244 (ARRY-886). May 16, 2008 691
Amgen Highlights Data to Be Presented at ASCO. May 16, 2008 2940
Significant Data on ERBITUX(R) (cetuximab) and ImClone Pipeline to Be Presented at American Society of Clinical Oncology 2008 Annual Meeting. May 16, 2008 1736
ERBITUX(R) (cetuximab) Data Demonstrate Improvements in Response Rate and Progression-Free Survival in Wild Type K-Ras Metastatic Colorectal Cancer Patients in First-Line Setting. Clinical report May 16, 2008 1505
New Data on Bristol-Myers Squibb Oncology Compounds to Be Featured in More Than 100 Abstracts at ASCO 2008. May 15, 2008 507
IMS Health Forecasts Continued Double-Digit Annual Growth of Cancer Therapeutics: Global Sales Expected to Exceed $75 Billion by 2012. Disease/Disorder overview May 15, 2008 800
Sirtex Sponsors Pilot Study Evaluating SIR-Spheres(R) Microspheres for the Treatment of Unresectable Hepatocelluar Carcinoma. May 14, 2008 615
Cellceutix Obtains Initial Funding to Advance Its Head and Neck Cancer Drug. May 14, 2008 266
Phase II Study of IMC-A12 for Advanced Liver Cancer Opens for Patient Enrollment. Report May 13, 2008 1018
Nanomedicine company Nanobiotix elects former Aventis vice chairman and CFO Patrick Langlois as its chairman. May 12, 2008 445
Lymphoma Drug Pipeline Update Lists All Drugs And Gives You A Progress Analysis On Each One Of Them. May 12, 2008 401
OncoVista Innovative Therapies' Information to Be Available Through S&P Market Access Program. May 8, 2008 498
VioQuest Pharmaceuticals Announces Issuance of U.S. Patent. May 7, 2008 824
Minerva Biotechnologies Announces Major Breakthrough on New Cancer Therapy Target MUC1*. May 5, 2008 395
BSD Medical to Present Its Cancer Therapy Systems at the 2008 World Congress of Brachytherapy. May 2, 2008 355
Labor Finders International. Brief article May 1, 2008 33
Sirtex Supports the Fourth Annual Clinical Symposium on Liver-Directed Microsphere Therapy Dedicated to Advancing Treatments for Patients with Inoperable Metastatic Liver Cancer. Apr 24, 2008 657
BIOMAX INFORMATICS AG Selected as a Consortium Partner in the Newly Formed Center for Personalized Cancer Medicine (OncoTyrol). Apr 23, 2008 680
Immunicon Corporation Receives Grant to Develop Test for Residual Disease in Leukemia Patients. Apr 22, 2008 1006
Pfizer Japan Receives Manufacturing and Marketing Authorization for SUTENT. Apr 21, 2008 857
Advaxis' Listeria Monocytogenes-Based Vaccine Garners National Media Attention. Apr 18, 2008 966
Spectrum Pharmaceuticals Presents Data on Lucanthone, a Novel Anticancer Drug, at the Meeting of the American Association of Cancer Research. Apr 17, 2008 1121
European Regulatory Agency Grants Orphan Status to Morphotek(R)'s Farletuzumab and MORAb-009. Apr 16, 2008 711
VioQuest Pharmaceuticals' Novel Akt Inhibitor VQD-002 is Synergistic with Various Cancer Therapies in Preclinical Studies. Apr 16, 2008 1033
OSI Pharmaceuticals Summarizes Data Presented at the Annual Meeting of the American Association for Cancer Research. Apr 16, 2008 1630
Spectrum Pharmaceuticals Presents Data on SPI-1620, a Novel Adjunct to Chemotherapy, at the American Association of Cancer Research Meeting. Apr 15, 2008 1178
Sirtex Receives FDA Approval for FAST Clinical Trial. Apr 15, 2008 641
Xencor Presents Pre-Clinical Data for Anti-CD19 Antibody at AACR. Apr 15, 2008 554
Significant Tumor-Specific Immune Response Observed in AVANT's Phase 2 Trial Evaluating CDX-110 with Temozolomide for Treatment of Glioblastoma Multiforme. Apr 15, 2008 1504
MitoSciences Inc. and University of Oregon Complete Biotechnology Deal. Apr 15, 2008 667
TransMolecular Unveils First Data on TM601 Anti-Angiogenic Mechanism-of-Action at AACR Annual Meeting. Apr 14, 2008 810
ArQule Summarizes Abstracts Presented at AACR. Apr 14, 2008 639
Early Data on Amgen's Anti-Angiogenesis Pipeline Molecules Suggest Biologic Activity Across Tumor Types. Apr 13, 2008 1644
OncoVista Innovative Therapies, Inc. Announces Appointment of AdnaGen Chief Executive Officer. Apr 11, 2008 671
Onconova Therapeutics Announces Presentation of Clinical and Nonclinical Data on Lead Compound ON 01910.Na and New Sulfonamide Compounds at AACR. Apr 11, 2008 462
ArQule Provides Clinical Update on E2F-1 Program. Apr 10, 2008 923
New Report Assesses Key Trends in the Political and Reimbursement Environment for Cancer Drugs. Apr 10, 2008 462
Phase II Study of IMC-A12 for Advanced Head and Neck Cancer Commences Patient Enrollment. Clinical report Apr 9, 2008 1518
Cancer Stem Cells Created With Technique Developed at Stanford. Apr 9, 2008 798
Zacks Analyst Interview Highlights: Dendreon Corp. and Genta, Inc. Apr 8, 2008 559
Seattle Genetics Announces Initiation of Phase Ib Clinical Trial of SGN-40 in Combination with Rituxan and Gemzar for Non-Hodgkin Lymphoma. Apr 8, 2008 785
Gain Competitive Insight into 123 Anti-Angiogenic Drugs, under Development by 90 Investigators. Apr 8, 2008 533
Prognostic and predictive molecular markers in colorectal cancer: inhibition of the epidermal growth factor receptor. Stohlmacher, Jan Mar 1, 2008 2117
Feasibility of sequential therapy with FOLFIRI followed by docetaxel/cisplatin in patients with radically resected gastric adenocarcinoma: a randomized phase III trial. Rougier, Philippe Mar 1, 2008 1352
FDA rules on use of Avastin for breast cancer. Feb 26, 2008 570
Dendreon drug will have to wait for FDA. Brief article Feb 26, 2008 279
Tainted drugs tied to Chinese supplier of abortion drug. Feb 12, 2008 724
Egenix Licenses Harvard Anti-Cancer Platform. Feb 1, 2008 198

Terms of use | Copyright © 2008 Farlex, Inc. | Feedback | For webmasters | Submit articles